Introduction
Osteosarcoma is the most common primary malignant bone tumor in children and adolescents, yet its absolute incidence among malignant tumors is low. The incidence of newly diagnosed cases peaks in the second decade of life (1) . As osteosarcoma may produce various kinds of extra cellular matrix and have different degrees of differentiation, huge variability exists in histological patterns. Conventional osteosarcoma can be divided into osteoblastic, chondroblastic, and fibroblastic subtypes depending on the predominant type of extracellular matrix (2) . The etiology of osteosarcoma in young patients is unexplained. Osteosarcoma could potentially derive from any cell on the differentiation pathway between a mesenchymal stem cell and a mature osteoblast (3) .
The goal of bone sarcoma therapy is curing the patient of both the primary tumor and all (micro-) metastatic deposits while maintaining maximal extremity function and minimalizing treatmentspecific late side effects. Bone sarcoma therapy involves close multidisciplinary coordination of oncologists, orthopedic surgeons, musculoskeletal pathologists and radiologists. It usually consists of induction neoadjuvant chemotherapy followed by local therapy of the primary tumor and any primary metastases, and adjuvant chemotherapy. Local treatment for osteosarcoma should be surgery whenever possible (4) . After the introduction of adjuvant chemotherapy in the 1970s, survival has increased from 10-20% to 50-80%. Doxorubicin, cisplatin, ifosfamide and methotrexate are currently the most effective agents for patients with osteosarcoma (5) . Advances in imaging, new materials, and prostheses have assisted surgeons in making more accurate preoperative plans and giving them a broader range of operative alternatives. worse then location of extremities, are reported to be independent prognostic factors of osteosarcoma (6) . At the time of diagnosis, 20% of patients already present with distant metastases, with lung the most frequent metastatic site (5) . The prognosis of patients with recurrent disease or metastases at diagnosis is poor. Resection of pulmonary metastases is a standard treatment for lung relapse of a tumor. Survival of patients who have surgery is 36% after 5 years, and 26% after 10 years (7) . Unresectable tumors increase the risk of local recurrence and result in poor prognosis. (4) In this retrospective analysis, we collected data on children with osteosarcoma diagnosed between 1988 and 2006 in the Second Department of Pediatrics in Budapest. This disease is rare, so the aim of our study was to examine prognostic significance of factors based on a large cohort of patients homogeneous for ethnic group and treatment. Tumor Registry of Hungary) were diagnosed with osteosarcoma in Hungary. Osteosarcoma patients could be treated at three pediatric oncology centers in the country. The largest is the Second Department of Pediatrics in Budapest, where 70% of the subjects were treated (122 patients). We retrospectively collected clinical data on these patients (65 males and 57 females; mean age at diagnosis: 13.8 ± 3.6 standard deviation [SD] , range: 5.5-17.6 years).
The patients were treated according to the Cooperative Osteosarcoma Study Group (COSS) 86 (8) and later COSS 96 protocols (9) including neoadjuvant and adjuvant chemotherapy, and radical surgery (Figure 1 ). The differences between the two protocols were that the COSS 96 protocol had a shorter low-risk arm and introduced a new branch with increased methotrexate. In Hungary, we used only the standard arms. We did not randomize the study, so the two protocols had no relevant differences in drugs, dosage, or schedule. 
Results
For the entire cohort, the 5-year OS was 68% and the EFS 62% ( Figure 2 ). Results are in Table III . Of the 122 children, 37 had metastasis, local relapse or both ( Figure 3 ). Of 37 cases, 15
had early metastasis at the time of diagnosis, with an OS of 16.6%. In 11 cases, metastases were in the lungs, in 3 cases, in the bone, and in 1 case in the kidney. Only three patients with early metastases survived. In our patient population, 13 children had late metastases with an OS of 41.6%. All had pulmonary metastases, and four also had metastases in the regional lymphatic glands. Eight had both local relapse and metastasis. Late pulmonary metastases were treated with thoracotomy and postoperative chemotherapy in 13 children, with 5 surviving. The OS of nonmetastatic patients was 79% ( Figure 4A ). Dependence of OS on the time of metastasis appearance was significant (p = 0.00002).
Of 23 patients with local relapses, 18 died ( Figure 3 ). All patients with local recurrence relapsed despite primary tumor surgery. Limb salvage surgery was performed on 16 patients before relapse. Six patients had early metastases and local relapse together, and five of these died.
Eight patients had late metastases and local relapse together, and six died. Isolated local recurrence was found in 9 patients, with 2 long-term. The median time to develop local recurrence was 16 months from the date of diagnosis (range: 0.4-118.3 months).
We also analyzed by type of surgery ( Figure 4B ). All patients who did not undergo radical surgery died. Although 30 patients underwent an amputation, in the last 10 years more than 85%
of patients have undergone limb-salvage surgery, with most of them receiving tumor endoprothesis. EFS was 57% for amputation cases and 68% for limb-saving surgery cases. The survival rate of patients undergoing amputation was somewhat lower than those receiving limbsalvage surgeries, because orthopedists chose amputation for patients with a larger tumor volume There was no difference in survival between patients diagnosed before or after 1995 (p = 0.6) ( Figure 5A ). We chose 1995 as the cut-off because COSS 86 was used from 1988-1995, and COSS 96 was used from 1996-2006. In the group treated according to COSS 86, EFS was 57%; it was 64% for the group treated with COSS 96.
We analyzed the relationship between EFS and tumor site and found no significant difference in survival if the primary tumor was in the upper or lower extremity (p = 0.7). In both cases, EFS was around 60% (upper extremity 56.3% vs. lower extremity 65%), while tumors of the axial skeleton showed a much worse survival rate of 22.2% (p = 0.013) ( Figure 5D ).
Boys and girls showed the same survival rates (p = 0.5) (
Figure 5B), with an EFS of 65% for girls and 57% for boys. We observed no differences in survival rates between osteosarcoma histological subgroups (p=0.9) ( Figure 5C ). A significant difference was detected in survival rate between poor and good responders (p = 0.018). The EFS was 77% for good responders and 50%
for poor responders ( Figure 4C ). Significantly better results were achieved with patients younger than 14 years than with patients over 14 years (p = 0.008). While the EFS of the patients over 14 years was only 48.4%, the EFS of patients under 14 years was 74.1% ( Figure 4D ). We were unable to collect tumor volume data because 60% of these data were missing or incorrect because poor documentation. By multivariate analysis, the presence of metastases increased the risk for a new metastasis fivefold, but no other clinical or demographic characteristics were independently associated with metastasis risk (13). In patients with osteosarcoma of the extremity with lung metastases, a combination of aggressive chemotherapy with simultaneous resection of primary and metastatic tumors can be a therapeutic approach (16). In this study, the mean survival rate of patients with lung metastasis is 10-30%. The length of the relapse-free interval is also an important prognostic factor. In cases of early metastasis, almost all patients died while the OS rate of late metastatic patients was quite good in our study (42%). Patients with suspected or confirmed osteosarcoma should be evaluated and treated at a comprehensive cancer center within a multidisciplinary sarcoma program that includes pediatric, medical and radiation oncologists; orthopedic and surgical oncologists; musculoskeletal pathologists; and radiologists. Successful treatment involves adequate diagnosis, preoperative and adjuvant multiagent chemotherapy, and aggressive surgery with an emphasis toward limb preservation. Patients treated for osteosarcoma should be followed closely both for relapse of disease and for development of late effects from chemotherapy (24).
Osteosarcoma is a radioresistant lesion (24). Radiotherapy is used for palliative therapy in patients with radically inoperable tumors. Radiation therapy may represent an alternative to definite surgery in selected patients, in particular those with good response to chemotherapy, for whom surgery is either not feasible or refused (25). We used radiotherapy for palliative treatment in only two cases.
Based on this Hungarian population, we conclude that 68% of patients are curable through intensive chemotherapy and surgery. Limb-salvage surgery is not associated with a significantly 
